Semaglutide vs Tirzepatide vs Retatrutide: The Incretin Lineage, Explained

For most of pharmacology’s history, the dream was a magic bullet: one molecule, one target, one clean effect. Metabolic research has spent the last decade quietly doing the opposite. It started with a drug that hit a single gut-hormone receptor, then built one that hit two, then one that hit three — and at each step, the numbers in the trials moved. The story of semaglutide, tirzepatide and retatrutide is not really three separate stories. It is one lineage, told in receptors: single, then dual, then triple.²

Updated 1 October 2026. TRIUMPH-1 was published in the New England Journal of Medicine on 29 September 2026¹⁸. Weight-loss figures now name the statistical analysis they come from, and statements about availability were corrected. Retatrutide is not currently listed in Condor Research’s catalogue; this article is scientific context.

That lineage is worth understanding on its own terms, because it is one of the clearest illustrations in modern biochemistry of a simple idea — that the body’s metabolic control is not run by one switch but by a committee of hormones, and that pressing more of them at once does something different from pressing one harder. Here is how the committee works, and what the evidence actually shows.

What is an incretin, and why does it matter?

An incretin is a hormone released by the gut after eating that tells the pancreas to prepare for incoming glucose. The two principal incretins are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Add a third hormone, glucagon — which raises blood sugar and, counterintuitively, increases energy expenditure and influences how the liver handles fat — and you have the three receptors at the centre of this whole field.²⁵

The insight that reshaped the field was that these hormones do not work in isolation. GLP-1 blunts appetite and sharpens the insulin response to a meal. GIP modulates insulin secretion and fat metabolism. Glucagon, when carefully balanced against the others, can push energy use upward. Engineer a single peptide that engages more than one of these receptors at once, and the metabolic effects do not merely add — they appear to compound.²⁵⁶

How does semaglutide differ from tirzepatide and retatrutide mechanistically?

The cleanest way to see the difference is by generation. Semaglutide is a GLP-1 mono-agonist: it pulls a single lever, the GLP-1 receptor. Tirzepatide is a dual agonist, engaging both GIP and GLP-1 receptors — the first widely studied molecule to treat the incretin system as a pair rather than a solo.⁴ Retatrutide goes one further: it is a triple agonist, acting at the GIP, GLP-1 and glucagon receptors simultaneously.²⁵ Researchers have nicknamed it “the power of three” for exactly this reason.⁵

Why does adding receptors change outcomes? Because each receptor contributes a different metabolic effect, and the glucagon arm in particular brings something the others cannot: a thermogenic, energy-expenditure component layered on top of appetite suppression and improved glucose handling.²¹³ In preclinical work, this multi-hormonal approach has shown effects beyond glucose and weight — including, in mouse and hamster models of metabolic liver disease, measurable improvements in hepatic fat and fibrosis-related markers.¹⁰¹⁵

How much weight loss did each show in phase-3 trials?

This is where the lineage becomes legible in numbers. Across their respective phase-3 programmes, the average weight loss climbed roughly in step with the receptor count. In a 2025 head-to-head analysis comparing the three for weight loss, semaglutide sat near the bottom of the range and retatrutide at the top, with tirzepatide between them.⁴ Retatrutide’s TRIUMPH-1 trial reported 25.0% average weight loss at 80 weeks on its primary analysis (28.3% if every participant stays on treatment), published in the New England Journal of Medicine;¹⁸ the sponsor described the efficacy-estimand figures, which reached about 30% at 104 weeks in a selected extension subgroup, as among the most powerful yet recorded for an investigational metabolic agent.¹⁶¹⁷ In type 2 diabetes, the TRANSCEND-T2D-1 phase-3 trial published in The Lancet reported reductions in blood glucose alongside the weight effects.⁷⁹

The incretin lineage by receptors and generation. In a 2025 head-to-head analysis of the three for weight loss, average reduction rose with receptor count — semaglutide lowest, tirzepatide in the middle, retatrutide highest, the last reaching 25.0% at 80 weeks (28.3% on the efficacy estimand) in the TRIUMPH-1 phase-3 trial.⁴¹⁸¹⁶ Status: semaglutide and tirzepatide are approved medicines; retatrutide is investigational.

It is tempting to read that progression as a straight line of “more is better,” but the honest version is more interesting. The trials were run in different populations, at different times, under different protocols. The figures are not interchangeable, and a head-to-head within a single comparison is the only truly clean way to rank them — which is part of why direct studies like the 2025 head-to-head analysis matter so much.⁴

What does the honest evidence actually say?

Three things deserve emphasis. First, the dramatic figures come from a relatively young triple-agonist literature; retatrutide’s full long-term safety and durability profile is still being established across ongoing programmes, including dedicated trials in chronic kidney disease and cardiovascular-kidney-metabolic syndrome.³¹¹¹³ Second, much of the mechanistic detail — the adipose-tissue and liver effects, the lipid and metabolite shifts, the curious findings around alcohol-related behaviour in rats — comes from animal models and in vitro systems, not from settled human outcomes.^10121415 Those results are genuinely promising and genuinely preliminary; both can be true at once.

Third, and most important for anyone handling these materials: the legal and regulatory status of the three is not the same. Semaglutide and tirzepatide are approved medicines. Retatrutide is a late-stage investigational drug — it has not completed the regulatory journey, and the synthesis and characterisation literature around it is still actively developing.¹⁷⁸ Conflating “impressive trial data” with “available, approved treatment” is the single most common error in how this field is discussed publicly.

Why does the research-use-only distinction matter here?

Because the gap between an approved medicine, a trial drug and a research material is not a technicality — it is the whole point. Research-use-only (RUO) retatrutide is a laboratory material, and it is not the approved medicine, it is not the formulated drug used in the TRIUMPH or TRANSCEND trials, and it is not intended for human or veterinary use. Retatrutide is not currently listed in Condor Research’s catalogue; this article is scientific context. RUO material exists for laboratory investigation — receptor pharmacology, in vitro assays, animal-model work of the kind the references above describe — and nothing else.

In that context, the only things that matter about the physical material are the things a researcher can actually verify: identity, purity and a certificate of analysis (COA). A triple agonist is a precisely engineered peptide; whether a given vial contains what its label claims, at the stated purity, is a question for analytical chemistry, not marketing. If you are studying this lineage, the science deserves materials whose identity and purity are documented — and the rest, including any human application, sits firmly outside what RUO material is for. For the compound-specific background, see our overview of what retatrutide is.